Status:

UNKNOWN

A Trial of Rivaroxaban Versus Warfarin in Dissolving Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation

Lead Sponsor:

The Second Affiliated Hospital of Chongqing Medical University

Conditions:

Atrial Fibrillation

Left Atrial Appendage Thrombosis

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The purpose of this clinical randomized trial is to evaluate the efficacy and safety of rivaroxaban compared with warfarin in dissolving the LAA thrombus in patients with atrial fibrillation.

Detailed Description

Left atrial appendage (LAA) thrombosis is a common complication of atrial fibrillation and will significantly increase the incidence of stroke in patients. Warfarin is a classical oral anticoagulant w...

Eligibility Criteria

Inclusion

  • Get informed consent from the patient or family.
  • Non-valvular atrial fibrillation / atrial flutter.
  • The first transesophageal echocardiogram revealed a left atrial appendage thrombus (within 7 days of detection of thrombus).
  • Age at 18-80 years old.
  • CrCL≥ 30 mL/min (Cockcroft-Gault).
  • AST/ALT is less than 2 times the upper limit of normal.
  • Women of childbearing age need contraception.

Exclusion

  • Pregnant or lactating woman.
  • Can't understand or follow the research plan.
  • Patients under 18 or over 80 years old.
  • Low weight (\< 40 kg).
  • Previously found LAA thrombus and have taken anticoagulant drugs.
  • Patients with contraindications for anticoagulation.
  • Patients who need to use antiplatelet drugs simultaneously within 6-12 months after ACS or PCI.
  • A history of cerebral hemorrhage.
  • Patients with active bleeding.
  • Severe gastritis, gastroesophageal reflux patients.
  • Combination of P-glycoprotein inhibitors and other drugs in the presence of NOAC contraindications.
  • Patient with tumor. 14.Planned surgery within 3 months. 15.Other investigators believe that patients are not suitable for enrollment.

Key Trial Info

Start Date :

June 1 2019

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2022

Estimated Enrollment :

80 Patients enrolled

Trial Details

Trial ID

NCT03792152

Start Date

June 1 2019

End Date

December 30 2022

Last Update

March 19 2019

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.